Receptor News and Research

RSS

FDA designates Merck's lambrolizumab as Breakthrough Therapy for advanced melanoma

Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced today that the U.S. Food and Drug Administration has designated lambrolizumab (MK-3475) as a Breakthrough Therapy for the treatment of patients with advanced melanoma.

25 Apr 2013

Individuals with MEN1 are at increased risk of developing neuroendocrine tumors

A mutation in a protein called menin causes a hereditary cancer syndrome called MEN1 (multiple endocrine neoplasia type 1).

25 Apr 2013

Promising development for women with triple-negative breast cancer

Tamoxifen is a time-honored breast cancer drug used to treat millions of women with early-stage and less-aggressive disease, and now a University of Rochester Medical Center team has shown how to exploit tamoxifen's secondary activities so that it might work on more aggressive breast cancer.

24 Apr 2013

Research: DBS may provide therapeutic relief to binge eating

Deep brain stimulation in a precise region of the brain appears to reduce caloric intake and prompt weight loss in obese animal models, according to a new study led by researchers at the University of Pennsylvania.

24 Apr 2013

Individual cancer cells in blood stream are responsible for metastases in breast cancer patients

Individual cancer cells that break away from the original tumor and circulate through the blood stream are considered responsible for the development of metastases. These dreaded secondary tumors are the main cause of cancer-related deaths.

23 Apr 2013

Exposure to chemical pesticide has impacts that span multiple generations, say researchers

North Carolina State University researchers studying aquatic organisms called Daphnia have found that exposure to a chemical pesticide has impacts that span multiple generations - causing the so-called "water fleas" to produce more male offspring, and causing reproductive problems in female offspring.

23 Apr 2013

TSRI scientists find way to directly turn bone marrow stem cells into brain cells

In a serendipitous discovery, scientists at The Scripps Research Institute have found a way to turn bone marrow stem cells directly into brain cells.

23 Apr 2013

ARCA biopharma, Medtronic to study effectiveness of Gencaro for prevention of atrial fibrillation

ARCA biopharma, Inc., a biopharmaceutical company developing genetically-targeted therapies for cardiovascular diseases, today announced that it has entered into an agreement with Medtronic, Inc., a leader in medical technologies to improve the treatment of chronic diseases, including cardiac rhythm disorders, to collaborate on ARCA's proposed clinical trial, known as GENETIC-AF, of its lead developmental drug Gencaro (bucindolol hydrochloride).

From Medtronic 23 Apr 2013

Cerecor obtains exclusive, worldwide rights to NR2B receptor antagonist from Merck

Cerecor Inc, a neuroscience biotech company that develops therapies that have the potential to make a difference in diseases with high unmet medical needs, today announced that it has acquired exclusive, worldwide rights from Merck, known as MSD outside the United States and Canada, to develop and commercialize MK-0657, a small molecule NMDA receptor subunit 2B (NR2B) antagonist for all human indications, including depression.

22 Apr 2013

Aurigene and Endo’s collaborative efforts yield novel drug candidates

Aurigene and Endo entered into collaboration in 2009, for multiple integrated drug discovery programs in the areas of Inflammation and Oncology.

22 Apr 2013

3D image of cell signaling molecules indicates a trippable power switch

A three-dimensional image of one of the proteins that serves as an on-off switch as it binds to receptors on the surface of a cell suggests there may be a sort of main power switch that could be tripped. These surface receptors are responsible for helping cells discern light, set the heart racing, or detect pain.

22 Apr 2013

Researchers decipher the underlying mechanism of antiviral drug

A long-forgotten candidate for antiviral therapy is undergoing a renaissance: Since the 1970s, the small molecule CMA has been considered a potent agent against viral infections, yet it was never approved for clinical use.

22 Apr 2013

Shc plays key role in activating and controlling Erk

A protein which is intimately involved in cancer-promoting cell signaling also keeps a key component of the signaling pathway tied down and inactive, a team led by scientists from The University of Texas MD Anderson Cancer Center reports this week in Nature Structural Molecular Biology.

20 Apr 2013

Long winter months impact tamoxifen treatment for breast cancer

For women diagnosed with a form of breast cancer known as estrogen receptor positive (ER+) breast cancer, tamoxifen is an essential drug used in the treatment and prevention of recurring breast cancer.

19 Apr 2013

Arthritis drug reduces dry eye disease

Dry eye disease (DED) is a common condition that causes discomfort, visual disturbance and potentially damaging ocular surface inflammation that greatly impacts a person's quality of life.

19 Apr 2013

Targacept moving forward with Phase 2b study of TC-5619 for treatment of schizophrenia

Targacept, Inc., a clinical-stage biopharmaceutical company developing novel NNR Therapeutics, today announced that it has completed recruitment of patients in the Phase 2b study of TC-5619 as a treatment for negative symptoms and cognitive dysfunction in schizophrenia.

19 Apr 2013

ARMGO Pharma gets $1 million to support ARM210 preclinical work for DMD treatment

ARMGO Pharma and the Muscular Dystrophy Association today announced that $1 Million has been awarded for preclinical work in support of an Investigational New Drug application with the U.S. Food and Drug Administration for ARM210, a novel, orally available, small-molecule Rycal drug that has potential as a treatment for Duchenne muscular dystrophy.

18 Apr 2013

Eli Lilly reports positive results from Phase III AWARD trials of type 2 diabetes drug, dulaglutide

Eli Lilly and Company today announced positive top-line results of two additional Phase III AWARD trials for dulaglutide, an investigational, long-acting glucagon-like peptide 1 (GLP-1) receptor agonist being studied as a once-weekly treatment for type 2 diabetes.

18 Apr 2013

New research sheds light on successful ovulation and fertilization

Eggs take a long time to produce in the ovary, and thus are one of a body's precious resources. It has been theorized that the body has mechanisms to help the ovary ensure that ovulated eggs enter the reproductive tract at the right time in order to maximize the chance of successful fertilization.

18 Apr 2013

Preclinical data on anti-cancer activity of BI-505 published online in Cancer Cell

BioInvent International AB, a biotech company developing novel antibody therapeutics for treatment of cancer, today announced that the April 15, 2013 online issue of the highly prestigious cancer research journal Cancer Cell features a data publication demonstrating potent anti-cancer activity of BI-505 in multiple preclinical myeloma tumor models.

17 Apr 2013

Receptor News and Research

FDA designates Merck's lambrolizumab as Breakthrough Therapy for advanced melanoma

Individuals with MEN1 are at increased risk of developing neuroendocrine tumors

Promising development for women with triple-negative breast cancer

Research: DBS may provide therapeutic relief to binge eating

Individual cancer cells in blood stream are responsible for metastases in breast cancer patients

Exposure to chemical pesticide has impacts that span multiple generations, say researchers

TSRI scientists find way to directly turn bone marrow stem cells into brain cells

ARCA biopharma, Medtronic to study effectiveness of Gencaro for prevention of atrial fibrillation

Cerecor obtains exclusive, worldwide rights to NR2B receptor antagonist from Merck

Aurigene and Endo’s collaborative efforts yield novel drug candidates

3D image of cell signaling molecules indicates a trippable power switch

Researchers decipher the underlying mechanism of antiviral drug

Shc plays key role in activating and controlling Erk

Long winter months impact tamoxifen treatment for breast cancer

Arthritis drug reduces dry eye disease

Targacept moving forward with Phase 2b study of TC-5619 for treatment of schizophrenia

ARMGO Pharma gets $1 million to support ARM210 preclinical work for DMD treatment

Eli Lilly reports positive results from Phase III AWARD trials of type 2 diabetes drug, dulaglutide

New research sheds light on successful ovulation and fertilization

Preclinical data on anti-cancer activity of BI-505 published online in Cancer Cell

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News